Pediatric Serum Sickness Clinical Presentation
- Author: Tova Ronis, MD; Chief Editor: Harumi Jyonouchi, MD more...
The onset of serum sickness symptoms usually occurs 1-2 weeks after administration of the offending agent and correlates with the peak of circulating immune complexes. Fever, malaise, and headache are the earliest symptoms. Rash, joint pain, edema, gastrointestinal (GI) symptoms, arthralgia, and other symptoms follow.
A rash is often the first clinical symptom and is frequently pruritic. If the causal agent was injected, the rash typically starts at the site of injection. Otherwise, the rash starts on the abdomen and spreads outward. Mucous membranes are not involved. Eruption over the rest of the body is usually symmetric and may take any of the following forms:
Urticaria (see image below)
Erythema, petechiae, or purpura with a serpiginous border at the margin of palmar plantar skin with the use of ATG 
Approximately two thirds of patients experience joint discomfort. In order of decreasing frequency, the affected joints include the knees, ankles, shoulders, wrists, spine, and temporomandibular joint. Joint fluid usually yields a moderately high number of white cells. Myalgias in the arms and thighs may also occur.
Lymphadenopathy coincides with the onset of other symptoms of serum sickness. Lymph nodes that receive drainage from the injection site may enlarge and become tender. Other lymph nodes may also enlarge, sometimes to several centimeters in diameter.
Proteinuria, microscopic hematuria, and hyaline casts may be observed. Serum creatinine levels may transiently rise, and the creatinine clearance may decrease. Edema may be due to proteinuria or rash.
Nausea, vomiting, and abdominal pain are usually mild but may be confused with appendicitis and other GI disorders in children. Other, rare symptoms include:
Headache and blurred vision
Cardiovascular problems - Pericardial effusion
Respiratory problems - Dyspnea, wheezing, cyanosis
Since this condition is associated with immune complex-based bascular inflammation, in severe cases, involvement of other organs such as the kidney, brain, lung, GI tract, etc. can occur. For example, severe cases of serum sickness with sulfonamide can manifest as Stevens-Johnson syndrome.
von Pirquet CF, Schick B (Translator). Serum Sickness. Baltimore: Williams & Wilkins Co; 1951.
Gamarra RM, McGraw SD, Drelichman VS, Maas LC. Serum sickness-like reactions in patients receiving intravenous infliximab. J Emerg Med. 2006 Jan. 30(1):41-4. [Medline].
Colton RL, Amir J, Mimouni M, Zeharia A. Serum sickness-like reaction associated with griseofulvin. Ann Pharmacother. 2004 Apr. 38(4):609-11. [Medline].
Creamer JD, McGrath JA, Webb-Peploe M, Smith NP. Serum sickness-like illness following streptokinase therapy. A case report. Clin Exp Dermatol. 1995 Nov. 20(6):468-70. [Medline].
Heckbert SR, Stryker WS, Coltin KL, Manson JE, Platt R. Serum sickness in children after antibiotic exposure: estimates of occurrence and morbidity in a health maintenance organization population. Am J Epidemiol. 1990 Aug. 132(2):336-42. [Medline].
Hosoda N, Sunaoshi W, Shirai H, Bando Y, Miura H, Igarashi M. Anticarbamazepine antibody induced by carbamazepine in a patient with severe serum sickness. Arch Dis Child. 1991 Jun. 66(6):722-3. [Medline]. [Full Text].
King BA, Geelhoed GC. Adverse skin and joint reactions associated with oral antibiotics in children: the role of cefaclor in serum sickness-like reactions. J Paediatr Child Health. 2003 Dec. 39(9):677-81. [Medline].
Kunnamo I, Kallio P, Pelkonen P, Viander M. Serum-sickness-like disease is a common cause of acute arthritis in children. Acta Paediatr Scand. 1986 Nov. 75(6):964-9. [Medline].
Platt R, Dreis MW, Kennedy DL, Kuritsky JN. Serum sickness-like reactions to amoxicillin, cefaclor, cephalexin, and trimethoprim-sulfamethoxazole. J Infect Dis. 1988 Aug. 158(2):474-7. [Medline].
Segal AR, Doherty KM, Leggott J, Zlotoff B. Cutaneous reactions to drugs in children. Pediatrics. 2007 Oct. 120(4):e1082-96. [Medline].
Vial T, Pont J, Pham E, et al. Cefaclor-associated serum sickness-like disease: eight cases and review of the literature. Ann Pharmacother. 1992 Jul-Aug. 26(7-8):910-4. [Medline].
Lawley TJ, Bielory L, Gascon P, et al. A prospective clinical and immunologic analysis of patients with serum sickness. N Engl J Med. 1984 Nov 29. 311(22):1407-13. [Medline].
Knowles S, Shapiro L, Shear NH. Serious dermatologic reactions in children. Curr Opin Pediatr. 1997 Aug. 9(4):388-95. [Medline].
Kearns GL, Wheeler JG, Childress SH, Letzig LG. Serum sickness-like reactions to cefaclor: role of hepatic metabolism and individual susceptibility. J Pediatr. 1994 Nov. 125(5 Pt 1):805-11. [Medline].
Black RE, Gunn RA. Hypersensitivity reactions associated with botulinal antitoxin. Am J Med. 1980 Oct. 69(4):567-70. [Medline].
Jurkovich GJ, Luterman A, McCullar K, et al. Complications of Crotalidae antivenin therapy. J Trauma. 1988 Jul. 28(7):1032-7. [Medline].
Shemesh IY, Kristal C, Langerman L, Bourvin A. Preliminary evaluation of Vipera palaestinae snake bite treatment in accordance to the severity of the clinical syndrome. Toxicon. 1998 Jun. 36(6):867-73. [Medline].
Lavonas EJ, Kokko J, Schaeffer TH, Mlynarchek SL, Bogdan GM, Dart RC. Short-term outcomes after Fab antivenom therapy for severe crotaline snakebite. Ann Emerg Med. 2011 Feb. 57(2):128-137.e3. [Medline].
LoVecchio F, McBride C. Scorpion envenomations in young children in central Arizona. J Toxicol Clin Toxicol. 2003. 41(7):937-40. [Medline].
Isbister GK. Safety of i.v. administration of redback spider antivenom. Intern Med J. 2007 Dec. 37(12):820-2. [Medline].
Bielory L, Gascon P, Lawley TJ, et al. Human serum sickness: a prospective analysis of 35 patients treated with equine anti-thymocyte globulin for bone marrow failure. Medicine (Baltimore). 1988 Jan. 67(1):40-57. [Medline].
da Silva PS, Passos RM, Waisberg DR, Park MV. Serum sickness and severe acute renal failure after rabbit antithymocyte globulin treatment in aplastic anemia: a case report. J Pediatr Hematol Oncol. 2011 Jan. 33(1):43-6. [Medline].
Hanauer SB, Feagan BG, Lichtenstein GR, et al. Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet. 2002 May 4. 359(9317):1541-9. [Medline].
Colombel JF, Loftus EV Jr, Tremaine WJ, et al. The safety profile of infliximab in patients with Crohn's disease: the Mayo clinic experience in 500 patients. Gastroenterology. 2004 Jan. 126(1):19-31. [Medline].
Lees CW, Ali AI, Thompson AI, et al. The safety profile of anti-tumour necrosis factor therapy in inflammatory bowel disease in clinical practice: analysis of 620 patient-years follow-up. Aliment Pharmacol Ther. 2009 Feb 1. 29(3):286-97. [Medline].
Zabana Y, Domènech E, Mañosa M, et al. Infliximab safety profile and long-term applicability in inflammatory bowel disease: 9-year experience in clinical practice. Aliment Pharmacol Ther. 2010 Mar. 31(5):553-60. [Medline].
Wang J, Wiley JM, Luddy R, et al. Chronic immune thrombocytopenic purpura in children: assessment of rituximab treatment. J Pediatr. 2005 Feb. 146(2):217-21. [Medline].
Bennett CM, Rogers ZR, Kinnamon DD, et al. Prospective phase 1/2 study of rituximab in childhood and adolescent chronic immune thrombocytopenic purpura. Blood. 2006 Apr 1. 107(7):2639-42. [Medline].
Sailler L. Rituximab off label use for difficult-to-treat auto-immune diseases: reappraisal of benefits and risks. Clin Rev Allergy Immunol. 2008 Feb. 34(1):103-10. [Medline].
Kumar A, Khamkar K, Gopal H. Serum sickness and severe angioedema following rituximab therapy in RA. Int J Rheum Dis. 2012 Feb. 15(1):e6-7. [Medline].
Ungprasert P, Srivali N, Kittanamongkolchai W, Leeaphorn N, Griger DT. Rituximab-induced serum sickness in overlapping syndrome between sjögren syndrome and systemic lupus erythematosus. J Clin Rheumatol. 2013 Sep. 19(6):360. [Medline].
Goto S, Goto H, Tanoshima R, et al. Serum sickness with an elevated level of human anti-chimeric antibody following treatment with rituximab in a child with chronic immune thrombocytopenic purpura. Int J Hematol. 2009 Apr. 89(3):305-9. [Medline].
Hellwig K, Schimrigk S, Fischer M, et al. Allergic and nonallergic delayed infusion reactions during natalizumab therapy. Arch Neurol. 2008 May. 65(5):656-8. [Medline].
Pilette C, Coppens N, Houssiau FA, Rodenstein DO. Severe serum sickness-like syndrome after omalizumab therapy for asthma. J Allergy Clin Immunol. 2007 Oct. 120(4):972-3. [Medline].
Russo EA, Iacucci M, Lindsay JO, et al. Survey on the use of adalimumab as maintenance therapy in Crohn's disease in England and Ireland. Eur J Gastroenterol Hepatol. 2010 Mar. 22(3):334-9. [Medline].
Comenzo RL, Malachowski ME, Meissner HC, Fulton DR, Berkman EM. Immune hemolysis, disseminated intravascular coagulation, and serum sickness after large doses of immune globulin given intravenously for Kawasaki disease. J Pediatr. 1992 Jun. 120(6):926-8. [Medline].
Azik FM, Kanmaz G, Ileri T. Serum sickness-like syndrome after immunoglobulin M-enriched polyclonal immunoglobulin. Drug Metabol Drug Interact. 2010. 25(1-4):49-50. [Medline].
Wise RP, Iskander J, Pratt RD, et al. Postlicensure safety surveillance for 7-valent pneumococcal conjugate vaccine. JAMA. 2004 Oct 13. 292(14):1702-10. [Medline].
Bonds RS, Kelly BC. Severe serum sickness after H1N1 influenza vaccination. Am J Med Sci. 2013 May. 345(5):412-3. [Medline].
Aujero MP, Brooks S, Li N, Venna S. Severe serum sickness-like type III reaction to insulin detemir. J Am Acad Dermatol. 2011 Jun. 64(6):e127-8. [Medline].
Zhang Z, Xiang Y, Wang B, Chen H, Cai X, Wang X, et al. Intestinal mucosal permeability of children with cefaclor-associated serum sickness-like reactions. Eur J Pediatr. 2013 Apr. 172(4):537-43. [Medline].
Suwansrinon K, Jaijareonsup W, Wilde H, Benjavongkulchai M, Sriaroon C, Sitprija V. Sex- and age-related differences in rabies immunoglobulin hypersensitivity. Trans R Soc Trop Med Hyg. 2007 Feb. 101(2):206-8. [Medline].
Bielory L, Yancey KB, Young NS, Frank MM, Lawley TJ. Cutaneous manifestations of serum sickness in patients receiving antithymocyte globulin. J Am Acad Dermatol. 1985 Sep. 13(3):411-7. [Medline].
Biuk D, Jukic T, Vukojevic N, Kalauz M. Serum sickness and uveitis. Coll Antropol. 2005. 29 Suppl 1:127-8. [Medline].
Tolpinrud WL, Bunick CG, King BA. Serum sickness-like reaction: histopathology and case report. J Am Acad Dermatol. 2011 Sep. 65(3):e83-5. [Medline].
Nangaku M, Couser WG. Mechanisms of immune-deposit formation and the mediation of immune renal injury. Clin Exp Nephrol. 2005 Sep. 9(3):183-91. [Medline].
Tanriover B, Chuang P, Fishbach B, et al. Polyclonal antibody-induced serum sickness in renal transplant recipients: treatment with therapeutic plasma exchange. Transplantation. 2005 Jul 27. 80(2):279-81. [Medline].